| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Nilotinib | CTRPv2 | pan-cancer | AAC | 0.45 | 1e-18 |
| mRNA | BHG712 | GDSC1000 | pan-cancer | AAC | 0.42 | 5e-18 |
| mRNA | TL-1-85 | GDSC1000 | pan-cancer | AAC | 0.37 | 2e-14 |
| mRNA | VNLG/124 | GDSC1000 | pan-cancer | AAC | 0.4 | 6e-14 |
| mRNA | Axitinib | CTRPv2 | pan-cancer | AAC | 0.35 | 1e-13 |
| mRNA | masitinib | GDSC1000 | pan-cancer | AAC | 0.38 | 6e-13 |
| mRNA | Imatinib | CTRPv2 | pan-cancer | AAC | 0.36 | 9e-13 |
| mRNA | Nilotinib | GDSC1000 | pan-cancer | AAC | 0.4 | 7e-11 |
| mRNA | KIN001-102 | GDSC1000 | pan-cancer | AAC | 0.31 | 5e-10 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | 0.31 | 8e-10 |